PD-1 inhibition plus chemoradiotherapy is effective across ethnicities in locally advanced cervical cancer
However, studies highlight cost as an obstacle to widespread accessibility in some countries
The promises of antibody-drug conjugates for ovarian cancer
A multitude of new agents under development could finally offer meaningful treatment options to a patient population with high unmet need
A phase I study shows a promising strategy to overcome resistance to immunotherapy in cancer
Safety and efficacy data of a PD-1/IL-2 bispecific antibody fusion protein were presented at an ESMO Virtual Plenary
Atezolizumab plus sacituzumab govitecan show encouraging activity in inoperable triple-negative breast cancer
Efficacy and safety of the first-line novel combination were assessed in patients with untreated PD-L1 positive locally advanced or metastatic tumours
Triplet therapy shows promise in patients with ER positive/HER2 negative metastatic breast cancer
A synergic effect of olaparib, durvalumab and fulvestrant was observed across different mutated subgroups, with higher benefits in BRCA 1 and 2 carriers
Atezolizumab does not improve prognosis in early relapsing advanced triple-negative breast cancer
However, a higher objective response rate with atezolizumab was reported in the IMpassion132 trial suggesting that at least some patients could benefit from it
Adjuvant immunotherapy improves overall survival in renal-cell carcinoma
Updated results from the KEYNOTE-564 trial confirm the role of pembrolizumab after surgery
Treating colorectal cancer in the biomarker era – what's next?
In an interview, Prof. Julien Taieb comments on the major advances from colorectal cancer research which are driving the development of molecular-based therapies
Research in upper gastrointestinal cancers makes a leap forward
In the last few years, study findings have changed clinical practice and offered new opportunities of care to many patients
A study shows correlation between fatty acids intake and response to immunotherapy
Dietary regimens may alter the microbiome composition, increasing bacteria with a beneficial immunogenic effect